DOCSLIB.ORG

Pfizer Decides to Keep Consumer Healthcare

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pfizer Decides to Keep Consumer Healthcare OTC29-07-11p1&28FIN.qxd 29/7/11 10:13 Page 1 29 July 2011 COMPANY NEWS 2 RB expands Mucinex 2 Pfizer decides to keep as generics loom Ransom sells contract 3 manufacturing arm Consumer Healthcare J&J’s US OTC sales 4 halve in two years Forest Laboratories buys 5 fizer has decided to keep its Consumer pharmaceutical products”, Read pointed out, six OTC brands from GSK PHealthcare business following a review and also had “strong connections with emerging Hi Capital acquires stake 6 of all its operations. markets and pharmacy customers worldwide”. in Pharmacy Chain 36.6 However, the US-based pharmaceutical com- Read’s comments seem to bring an end to a Novartis looks to grow 7 pany is exploring the strategic alternatives, in- period of uncertainty for the Consumer Health- OTC business cluding divestment, for its Animal Health and care business, which Pfizer gained when it ac- Emerging markets to dominate 8 Nutrition businesses. quired Wyeth in October 2009 (OTC bulletin, at GSK Ian Read, Pfizer’s president and chief exec- 30 October 2009, page 3). DocMorris keeps growing 9 utive officer,said the company believed it could In February of this year,Read – who took as new customers log on continue to “enhance the value” of the Con- the reins at Pfizer in December 2010 – chal- FDA files decree against 10 sumer Healthcare business, which he insisted lenged the Consumer Healthcare business to dietary supplement firm had a “strong connection” to the company’s prove its worth to Pfizer (OTC bulletin,11 Feb- core biopharmaceutical operations. ruary 2011, page 14). GENERAL NEWS 11 Consumer Healthcare had the potential to Read’s comments coincided with Consumer “extend the value of certain Pfizer legacy bio- ■ Continued on page 16 Commission plans repeal of 11 law covering dietetic foods Eisai moves to switch 12 rabeprazole in the UK EFSA releases fifth batch 13 Centralised sumatriptan switch rejected of opinions on health claims Counterfeit Directive leaves 14 alpharm’s bid to gain non-prescription sta- ient would increase the risk of cerebrovascu- much to do Gtus for the migraine medicine sumatriptan lar and cardiovascular side-effects, and poten- US court backs Watson 15 using Europe’s centralised procedure has been tial misuse”. in Mucinex patent case turned down. In addition, the CHMP felt that monitoring Germany defers paracetamol 16 The rejection comes despite the fact that was essential because migraine as a condition decision sumatriptan is already a non-prescription med- changed over time, as did the patient’s cere- icine for treating migraine in some countries, brovascular and cardiovascular status. MARKETING NEWS 17 including New Zealand, Sweden and the UK. The measures proposed by Galpharm to re- Furthermore, medicines for treating the symp- duce these risks were “insufficient”, according Beiersdorf boosts Eucerin 17 toms of migraine are available without a pre- to the members of the CHMP. range for acne-prone skin scription in many countries. Sumatriptan Galpharm was developed as a Hedrin expands in the UK 18 Europe’s Committee for Medicinal Products generic version of GlaxoSmithKline’s Imigran. with ‘fuss-free’ treatment for Human Use (CHMP) decided Sumatriptan The CHMP accepted that it was bioequivalent FEATURES 20 Galpharm – containing 50mg sumatriptan – to Imigran. could not be approved in the non-prescription Overall, the CHMP concluded that the ben- Developing regions drive 20 setting. The CHMP maintained that “lack of efits of making Sumatriptan Galpharm avail- OTC growth medical supervision and monitoring of the pat- ■ Continued on page 13 A look at global OTC trends REGULARS Events – Our regular listing 19 Shotter to leave Germany’s Merck KGaA People – Brossard replaces Cotard 26 as head of France’s AFIPA eter Shotter will step down as worldwide Udit Batra, head of global public health and People – Reckitt promotes Pane 27 Phead of Merck KGaA’s Consumer Health market access at Novartis’ Vaccines and Diag- to global healthcare position Care division on 1 September 2011 and leave nostics unit, has been named as his replacement. the German company by the end of the year. ■ Continued on page 13 OTC29-07-11p2-3FIN.qxd 29/7/11 08:55 Page 2 OTC COMPANY NEWS Business Strategy/First-Half Results RB expands Mucinex as generics loom eckitt Benckiser has expanded the reach cinex line until 28 April 2020 (see page 15). quired SSL International last November (OTC Rof its Mucinex brand into the US multi- Becht admitted that the case against Watson bulletin,30 July 2010, page 1) – added £344 symptom cold category,as the company pre- had been lost and that the generics firm would million, the company said. On a like-for-like pares for the impact of generic competition to be in a position to launch its own versions of basis, total sales had advanced by 11%. the brand’s core cough products. “pretty much the full line” of Mucinex guaife- The Healthcare business had benefitted from Bart Becht, Reckitt Benckiser’s outgoing nesin-based cough products once the generics the “very good growth” achieved by the Mu- chief executive officer,said the Mucinex Fast- had been approved by the US Food and Drug cinex, Nurofen and Strepsils brands, Reckitt Max range of liquid products had been devel- Administration (FDA). Benckiser pointed out, all of which had been oped to treat a variety of symptoms associated Reckitt Benckiser is also facing a Mucinex boosted by line extensions and a stronger cold with colds and would help mitigate the impact patent challenge from Perrigo and has already and flu season. Gaviscon had also been a good of generic competition to Mucinex’ existing settled a case with URL/Mutual. contributor,the company noted. cough products. The new line of Mucinex products consists Looking ahead, the Strepsils brand would The US Court of Appeals recently upheld of four liquids: Mucinex Fast-Max Cold, Flu be extended in the second half of 2011, Kapoor a decision that Watson Pharmaceuticals’ guai- & Sore Throat; Mucinex Fast-Max Severe Con- said, with the launch of Strepsils Children 6+ fenesin tablets did not infringe the US patent gestion & Cough; Mucinex Fast-Max Cold & and Strepsils Sore Throat & Cough. 6,372,252, which protects the established Mu- Sinus; and Mucinex Fast-Max DM Max for Strepsils Children 6+ was the brand’s first Cough & Chest Congestion. lozenge specifically targeted at children, Kapoor Rakesh Kapoor,Reckitt Benckiser’s chief pointed out, while Strepsils Sore Throat & Cough executive officer designate, pointed out that each was the first lozenge that tackled tickly cough, Business Strategy of the four variants contained the maximum which he claimed was the number one symp- strength of active ingredients – including para- tom of a sore throat. Alliance Boots cetamol and phenylephrine – allowed for the In the Personal Care business, Dettol had symptoms each product was indicated to relieve. continued to grow in developing markets, Reck- The Mucinex brand would be entering a itt Benckiser said, as well as in Europe, where eyes China deal market segment “two-to-three times the size the rollout of the No Touch Hand Soap Sys- of the cough category”, Kapoor pointed out, but tem had been “very encouraging”. lliance Boots is in talks to acquire a hold- one which was also much more competitive. The Dettol brand would be expanded in Aing in Nanjing Pharmaceutical Group, the To ensure Mucinex could compete in this the second half of the year with the Dettol largest shareholder in Chinese pharmaceutical segment, Reckitt Benckiser had combined Healthy Touch Moisturising Sanitiser,Kapoor wholesaler Nanjing Pharmaceutical. the brand equity Mucinex had built up in the revealed, and a line of male personal-care The pan-European wholesaler and retailer cough category,Kapoor noted, with maximum products aimed at the Middle East and other said it had signed a letter of intent with Nanjing strength ingredients and a liquid formulation developing markets. and both companies believed the potential col- that was the best-tasting in the category. Reckitt Benckiser had also launched its laboration would provide “substantial support Meanwhile, Reckitt Benckiser saw a 45% rise first Durex condom product since acquiring to the Chinese government in its commitment in sales at constant exhcnage rates at its Health the brand, Kapoor noted. Durex Performax In- to healthcare reform over the next 10 years”. & Personal Care business to £1.54 billion (C1.74 tense, now available in France, had been de- Described as a “leading pharmaceutical billion) in the first half of 2011 (see Figure 1). signed to provide a “more intense experience wholesaler in China”, Nanjing reported sales Sales from the Durex and Scholl brands – for both men and women”, he said. of CNY15.3 billion (C1.7 billion) in 2010. which Reckitt Benckiser gained when it ac- OTC Nanjing’s primary customers were hospitals and retail chains, including its own stores, Al- Business First-half sales Change 2010/2011 (%) liance Boots pointed out, noting that the com- (£ millions) £CER* pany had established a strong position in its Health & Personal Care1,536 +44 +45 home province of Jiangsu as well as the key Fabric Care757 -6 -5 provinces of Anhui and Fujian, and had ex- Surface Care692 +1 +2 panded into seven further provinces. Home Care569 +1 +3 Alliance Boots announced in November Dishwashing 453 ±0 +1 last year that it intended to become a leading Other 105 –– player in the Chinese market and had identi- Household and Health & Personal Care 4,112 +14 +15 fied ways to increase its presence (OTC bul- letin,16 November 2010, page 3). Pharmaceuticals 360 +16 +22 At the time, a spokesperson for Alliance Food 149 +2 +8 Boots told OTC bulletin that the company was Total Reckitt Benckiser 4,621 +14 +15 looking at “several opportunities” and one might be “seized in the near future”.
Load more

Recommended publications
  • Confusing Brand Names: Nightmare of Medical Profession
    Original Article www.jpgmonline.com Confusing brand names: Nightmare of medical profession Rataboli PV, Garg A Department of Pharma- ABSTRACT cology and Therapeutics, Objective: India has more than 20,000 registered pharmaceutical manufacturers. Consequently, there is a Goa Medical College, Bambolim, Goa 403202, flood of brand names to choose from. We conducted this study to analyse and sort out the multitudinous India brand names thronging the Indian market, and identified those that could create a possible confusion. Materials and Methods: Recent issues of drug formularies like Indian Drug Review, Drug Index, and Monthly Correspondence: Index of Medical Specialities-India were checked and all the brand names given were included. Some other Amit Garg, MD brand names that are available with the pharmacists but are not included in these indexes were also included E-mail: [email protected] in the study for analysis. Observations: Potentially confusing brand names were sorted out and categorised according to the severity of damage they can cause if misinterpreted by the pharmacist or the patient. Subgroups were made according to the brand name, the generic name, and the manufacturers of the drug. Conclusion: Several brand names are strikingly identical, similar looking (orthographic), or similar sounding (phonological). Preventing this possible confusion is not the work of any one person involved. We describe the Received : 09-08-04 role of prescribing doctors, dispensing pharmacists, consumer patients, and the manufacturing companies to Review completed : 30-09-04 prevent “wrong prescribing” due to similarities in brand names. Accepted : 22-12-04 PubMed ID : 15793332 J Postgrad Med 2005;51:13-6 KEY WORDS: Identical; look-alike; sound-alike; confusing; brand names rescribing drugs with their brand name is an essential the patients, doctors, pharmacists, and the drug manufacturers were P part of medical practice.
    [Show full text]
  • Glaxosmithkline Bangladesh Limited (GSK)
    GlaxoSmithKline Bangladesh Limited (GSK) Recruitment and Selection Process of GlaxoSmithKline Bangladesh Limited: An Evaluation nd Date of Submission: 2 September, 2014 ©Daffodil International University DAFFODIL INTERNATIONAL UNIVERSITY Internship Report On Recruitment and Selection Process of GlaxoSmithKline Bangladesh Limited: An Evaluation Submitted To Dr. Zakir Hossain Dean& Professor Faculty of Business & Economics Daffodil International University Submitted By Ishrat Jahan ID: 131-14-1019 Masters of Business Administration Daffodil International University Date of Submission: 2nd September, 2014 ©Daffodil International University Letter of Transmittal September 2, 2014 To Dr. Zakir Hossain Dean & Professor Faculty of Business and Economics Daffodil International University Dhaka-1205 Subject: Submission of internship report on recruitment and selection process: An evaluation of GlaxoSmithKline Bangladesh Limited Sir, I am highly satisfied to submit my report on recruitment and selection process: an evaluation of GSK. For preparing this report I tried my best to accumulate relevant and upgraded information from available sources. In preparing this report, I tried my level best to make it a complete one and sincerely look forward to any possible correction. I am very glad because you also given the opportunity to prepare this report .I hope that this report will meet the standards of your judgments. Your Sincerely ---------------- Ishrat Jahan ©Daffodil International University i Certificate of the Supervisor This is to certify that the internship report titled ―Recruitment and Selection Process of GlaxoSmithKline Bangladesh Limited: An Evaluation‖, has been prepared by Ms. Ishrat Jahan bearing ID: 131-14-1019 under my supervision, a practical study on GlaxoSmithKline Bangladesh Limited. I think on the basic of declaration Ms.
    [Show full text]
  • Corporate Social Responsibility Report 2016 Walgreens Boots Alliance Is the First Global Pharmacy-Led, Health and Wellbeing Enterprise
    Corporate Social Responsibility Report 2016 Walgreens Boots Alliance is the first global pharmacy-led, health and wellbeing enterprise. Our purpose is to help people across the world lead healthier and happier lives. Our 2016 Corporate Social Responsibility Report covers the fiscal year that ended 31 August 2016. In this year’s report: Overview Marketplace Introduction ...................................................1 Our CSR goals .............................................2 28 Our vision, purpose and values ................3 Our approach to CSR .................................4 Contributing to the United Nations Sustainable Development Goals .............6 Transparency ........................................... 30 Our impact ...................................................8 Ethical Sourcing ...................................... 30 ........................... About our Company ................................. 10 External Stakeholders 31 Stakeholder engagement ....................... 12 Workplace Community 32 14 Employee Health and Wellbeing ........ 34 Equal Opportunities .............................. 36 Health and Wellbeing ............................. 16 Health and Safety ...................................37 Young People ........................................... 17 ...................................... Cancer Programs .....................................20 About this report 38 Data management process ................ 38 Environment Data ............................................................ 38 Community data
    [Show full text]
  • OSB Participant List by Research Area
    OSB Participant List by Research Area Contact Centers (CC) • AARP • Air Products and • American Drug Stores Chemicals • AAA • ABB • American Electric Power • Airbus • Accor • Abbott • American Express • Alcatel Lucent • American Electric Power • Abengoa • American International • Alcoa Group • American International • Abu Dhabi National Group Energy Company • Alcon • American Stores Company • Austin Energy • ACC Limited • Alfa • American Water • Bank of America • Access Insurance Holdings • Algonquin Power & • Amgen Utilities • Blue Cross Blue Shield • Accord Holdings • AMIL • ALH Group • Charles Schwab & • ACE • AmInvestment Bank Company • Alitalia • Acea • AMR • Citigroup • ALK Abello • Acer • Amssi • Citizens Gas • Alkermes • Acxiom • Amtran Logistics • Clarke American • Allergan • Adelaide Clinic Holdings • Andrew Corporation • CPS Energy • Alliance & Leicester • Adidas • Anglian Water Services • Direct Energy • Alliance Boots • Advance Food Company • Anritsu • Federal Reserve Bank of • Alliant Techsystems Minneapolis • Advance Publications • Anschutz • Allianz • John Deere • Advanced Coating • Apache • Allied Irish Banks • Technologies Louisville Water Company • Apex Equity Holdings • Advanced Semiconductor • Allstate Insurance • Manila Electric Company Engineering Company • Apple • • • Mellon Financial Adventist Health System Ally Financial • Arcadia Housing • • • MetLife Aegon Alon USA Energy • Arcos Dorados Holdings • • • Morgan Stanley AEON AlpTransit Gotthard • Ardent Health Services • • • NetBank Aera Energy Alstom • Argos •
    [Show full text]
  • Betterbusiness Betterfinancials How We Drive Growth and Outperformance
    Reckitt Benckiser Group plc Annual Report and Financial2015 Statements betterbusiness 2015 Reckitt Benckiser Group plc (RB) Annual Report and Financial Statements We make a difference to people’s lives through a trusted portfolio of brands, across consumer health, hygiene and home. Our vision Our purpose A world where people are To make a difference, by healthier and live better. giving people innovative solutions for healthier lives and happier homes. Our strategy betterbusiness betterfinancials How we drive growth and outperformance Chief Executive’s Review on pages 8–9 bettersociety betterenvironment How we support How we reduce our communities and our environmental develop our people impact Strategic framework on pages 12–13 Contents Strategic Report bettersociety Governance Report 1 Highlights 24 – Workplace 46 Board of Directors 2 At a glance 26 – Communities 50 Executive Committee 4 Chairman’s Statement 26 – Products 52 Chairman’s Statement on 7 Reasons why RB delivers betterenvironment Corporate Governance 8 Chief Executive’s Review 27 – Greenhouse gas emissions 54 Corporate Governance Statement 10 Our unique culture 28 – Water 60 Nomination Committee Report 12 Strategic framework 28 – Waste 61 Audit Committee Report 14 Our market and resources 29 – Sourcing 66 Directors’ Remuneration Report betterfinancials 30 Our operating model 68 Our remuneration at a glance 16 – Our strategy to deliver 32 Our operating model in action 70 Annual Report on Remuneration 17 – Organisation 34 Creating stakeholder value 79 Directors’ Remuneration Policy 19 – Powermarkets 36 Financial Review 85 Report of the Directors 20 – Powerbrands 40 Strategic Risks 88 Directors’ Statement of Responsibilities 22 – Virtuous earnings model Financial Statements 89 Financial Statements Any information contained in the 2015 Annual Report and Financial Statements on the price at which shares or other securities in Reckitt Benckiser Group plc have been bought or sold in the past, or on the yield on such shares or other securities, should not be relied upon as a guide to future performance.
    [Show full text]
  • Gilead and Glaxo's HIV Battle Intensifies
    February 14, 2017 Gilead and Glaxo’s HIV battle intensifies Madeleine Armstrong The first phase II data with Gilead’s HIV integrase inhibitor bictegravir have set up a showdown with Glaxosmithkline/Viiv Healthcare’s marketed product dolutegravir. But Glaxo is already one step ahead with data from a two-drug combo that could reduce the side-effect burden for HIV patients. Glaxo believes that this doublet could “reshape the whole game”, the group's chief executive, Andrew Witty, said on its fourth-quarter earnings call. HIV has been one of the group’s main drivers in recent quarters as it has taken market share from Gilead, which is becoming increasingly reliant on HIV as its hepatitis C franchise slows (see tables below). Bictegravir vs dolutegravir The phase II study, presented today at the Conference on Retroviruses and Opportunistic Infections in Seattle, compared bictegravir plus emtricitabine and tenofovir alafenamide – known as FTC/TAF – with dolutegravir plus FTC/TAF in 98 treatment-naive, HIV-infected adults. Both are the latest iterations of the integrase inhibitor class, and unlike older products with the same mechanism do not require boosting – taking another drug to raise circulating levels – so have a lower risk of adverse events and drug-drug interactions. The phase II trial found similar response rates with a bictegravir-containing regimen versus a dolutegravir- containing therapy, which should boost confidence in Gilead’s compound ahead of phase III readouts expected mid-year. It found a 97% response in the bictegravir arm at 24 and 48 weeks, versus 94% at week 24 and 91% at week 48 in the dolutegravir arm, but the difference was not statistically significant.
    [Show full text]
  • Pharma Pricing, Non-Profit Ties Get Increasing Scrutiny from Prosecutors
    REGULATORY UPDATE REGULATORY UPDATE CONSUMER DRUGS Pediatric Rare Disease Voucher Japan Wants EMA To Stay In Digital Marketing: Health Care Brands’ Program Faces Expiration, p. 12 UK Post-Brexit, p. 15 Window Into Consumers’ Lives, p. 20 Pharma intelligence Pinkpink.pharmamedtechbi.comSheetVol. 78 / No. 38 September 19, 2016 informa Mylan NV was subpoenaed for material Pharma Pricing, Non-Profit Ties Get about the pricing of its generic doxycycline and communications with competitors. And Valeant Pharmaceuticals International Inc. is Increasing Scrutiny From Prosecutors facing several probes about its pricing and BRENDA SANDBURG [email protected] patient assistance programs (see chart, p. 5). Mylan’s doxycycline price increases were called out by Sen. Bernie Sanders, I-Vt., and Rep. Elijah Cummings, D-Md., in October 2014 when they sent letters to 14 generic drug makers about the pricing of their prod- ucts. They noted that from October 2013 to April 2014, the average price charged for a 500-count bottle of 100 mg tablets had risen from $20 to $1,829, an 8,281% increase. Mylan is now under fire for repeatedly rais- ing the price of its severe allergy treatment EpiPen (epinephrine), which has increased from about $100 for a two-pack in 2008 to more than $600. Members of Congress sent a flurry of letters to the company requesting an explanation for the price hikes. And on Sept. 6, New York Attorney Gen- Shutterstock: blvdone Shutterstock: eral Eric Schneiderman announced that his office has begun an investigation into rug makers have been unable to programs, contractual agreements with Mylan with regard to EpiPen, saying a pre- shake free of government inves- pharmacy benefit managers, support of liminary review revealed that Mylan may Dtigations of their marketing and non-profit organizations, and calculation have inserted potentially anticompetitive sales practices.
    [Show full text]
  • 022450Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 022450Orig1s000 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S) CLINICAL PHARMACOLOGY REVIEW NDA 22-450 Submission Dates 05/13/2009 Brand Name - Generic Name IV acetaminophen Reviewer Ping Ji, Ph.D. Team Leader Suresh Doddapaneni, Ph.D. PM Primary Reviewers Ping Ji. Ph.D. PM Team Leader Yaning Wang, Ph.D. OCP Division Division of Clinical Pharmacology-II OND Division Division of Anesthesia, Analgesia, and Rheumatology Products Sponsor Cadence Pharmaceuticals, Inc. Relevant IND(s) 58,362 Submission Type; Code 505 (b) (2) P Formulation; Strength(s) Sterile solution for intravenous infusion, 1000 mg/vial Indication Treatment of acute pain and fever Proposed Dosing Regimen Single or repeated dose via a 15-minute intravenous infusion. The dose administered varied depending on age and body weight. Table of Contents Table of Contents.................................................................................................................1 1. Executive Summary.....................................................................................................2 1.1. Recommendations............................................................................................ 2 1.2. Phase IV Commitments................................................................................... 2 2. Question-Based Review...............................................................................................9 2.1. General Attributes...........................................................................................
    [Show full text]
  • Local Businesses – Large and Small
    Local Businesses – Large and Small The details of the local businesses documented below have been researched by the Local History Group. Thomas Glover & Son Thomas Glover & Son, elastic web and fabric manufacturers appeared in the Post Office Directory for Nottinghamshire in 1855. The company is recorded as having several addresses in Nottingham, however it had disappeared from the directory by 1900, returning in 1925 described as a surgical hosier in Chesterfield Street, Carlton. The firm remained at that address until the 1970s. The company’s buildings were on both sides of Chesterfield Street but are now demolished, new houses being built on the side. Turney Brothers In 1861 two brothers, Edward and John Turney built a tannery and began to make leather on a site next to the River Trent and the adjacent canal in Nottingham, known as Sneinton Island. The first buildings took up only a fraction of the space that by the 1920s had developed into a large site with labour-saving machinery imported from many countries. They traded under the name of Turney Brothers and had offices in London, Leicester and Manchester. Edward left some years after the commencement of the company and the driving force was John Turney who was in sole charge for over a quarter of a century. In 1888 the company re-organised into a Limited Company, John being chairman. John led an exceptionally distinguished social, political and commercial life. He was a member of Nottingham Corporation for 46 years, and became Sheriff and then Alderman in 1879 and Mayor for two years 1886 – 1888.
    [Show full text]
  • Rejuvenating RB Plc Group Benckiser Reckitt Annual Report and Financial Statements 2019 Statements Financial and Report Annual
    Rejuvenating RB Reckitt Benckiser Group plc Annual Report and FinancialStatements 2019 Reckitt Benckiser Group plc Annual Report and Financial Statements 20192018 INTRODUCTION CONTENTS Strategic Report Welcome 01 Financial highlights 02 Health and Hygiene Home – at a glance 04 Chairman’s statement 06 Chief Executive’s statement 10 Our business model Our purpose 12 How purpose drives our performance We exist to protect, heal and nurture in the relentless pursuit of a cleaner 14 Mapping what matters to our stakeholders and healthier world. 18 KPIs 20 Consumers Our fight 24 Customers We have a fight on our hands. A fight to make access to the highest quality 28 People hygiene, wellness and nourishment a right and not a privilege. 32 Partners 36 Communities 40 Environment 46 s172 statement 48 Health operating review 52 Hygiene Home operating review 56 Non-financial information statement 58 Financial review 64 Risk management Health 77 Viability statement Governance 78 Board of Directors 84 Executive Committee 86 Corporate Governance – Chairman’s statement 88 Corporate Governance statement 97 Nomination Committee Report 103 Audit Committee Report 111 CRSEC Committee Report 117 Directors’ Remuneration Report 138 Report of the Directors Page 48 141 Statement of Directors’ Responsibilities Financial Statements 143 Independent Auditors Report Chief Executive’s Statement 152 Financial Statements 223 Shareholder Information Hygiene Home Page 06 Page 52 STRATEGIC REPORT GOVERNANCE FINANCIAL STATEMENTS FINANCIAL HIGHLIGHTS Net Revenue Health Hygiene
    [Show full text]
  • In This Section
    Strategic report In this section Chairman’s statement 2 CEO’s review 4 Business overview 6 The global context 8 Our business model 12 Our strategic priorities 14 How we performed 16 Risk management 18 Grow 20 Deliver 32 Simplify 44 Our financial architecture 48 Responsible business 50 Financial review 58 Strategic report Chairman’s statement Chairman’s statement To shareholders The value of the significant changes that have been made in recent years is evidenced in our performance this year “ Since Sir Andrew became It is clear from the following pages that Through the Audit & Risk Committee, we the Group made good progress against oversee the issues and challenges faced by CEO, the company has its strategy in 2013. management, and encourage the creation of an environment in which GSK can achieve The Board believes the business is seeing returned £30 billion its strategic ambitions in a responsible and the benefits of the significant changes the sustainable manner. to shareholders.” management team has driven over recent years to deliver sustainable growth, reduce risk and I have no doubt that commercial success is enhance returns to shareholders. directly linked to operating in a responsible way and which meets the changing expectations of The notably strong performance from the society. In this respect, the company continues R&D organisation in 2013 – with six major to adopt industry-leading positions on a range new product approvals in areas including of issues. respiratory disease, HIV and cancer – is critical to the longer-term prospects of the The announcement of plans during 2013 to Group.
    [Show full text]
  • Biocentury 8.15.16
    WEEK OF AUGUST 15, 2016 6 PRODUCT DEVELOPMENT: NO ANTIGEN LEFT BEHIND Amgen has added to its immuno-oncology arsenal with its deal for Advaxis’ pan- epitope neoantigen vaccine platform. SERVING RETURNS 9 EMERGING COMPANY PROFILE: RESTRAINING TRANSLATION BY STEVE EDELSON, SENIOR EDITOR Bantam is developing small molecule eIF4E inhibitors to treat a range of cancers, China’s Ally Bridge Group hit the investment world’s starting with B cell malignancies. radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first fruits of that move with REGULATION: the listing of WuXi’s biologics unit in Hong Kong this 10 year, the question is what will be its next moves to ADAPTING FOR THE REAL WORLD generate outsized returns for its investors. EMA says better strategies for real-world evidence and more patient and payer involvement are necessary Ally Bridge, which has a about $1.5 billion under next steps for its adaptive pathway initiative. management across three funds and an international base of LPs, thinks its returns and continued visibility will come from a handful of public and private portfolio companies with transformative data events, the first of EBB & FLOW: 13 which should come this half. LION’S SHARE OF THE WORK Aslan’s validating event. Plus: Cutting a check The firm also says it is working on new private equity to Cleave; and Ironwood’s operating leverage. deals that will rival WuXi in terms of size and impact. Ally Bridge is keeping its private equity plans under wraps, and does not disclose names of investments in its Asia hedge fund.
    [Show full text]